Skip to main content
FDA declines to approve AZ drug for type 1 diabetes
7/16/2019

The FDA issued a complete response letter to AstraZeneca declining its application for Farxiga, or dapagliflozin, to be used as a supplement to insulin in adult patients with type 1 diabetes that do not respond adequately to insulin alone. The company plans to meet with the agency to decide its next action.

Full Story: